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A B S T R A C T
 
Background: Dengue is an infectious disease with a recurring incidence, especially in developing 
countries. Despite recent economic growth, success in disease control has not been achieved, 
and dengue has evolved from cyclic epidemic outbreaks to a lack of seasonality. The lack 
of scientific basis for the proper management of cases with hemorrhagic manifestations, 
especially regarding transfusion procedures, might contribute to the high death rate in 
potentially avoidable cases.
Objective: The aim of the study was to identify the clinical and laboratory manifestations in 
hemorrhagic dengue fever treated at the emergency services in Rio Branco, AC, Brazil, as well 
as to describe transfusion characteristics of patients and identify possible prognostic factors.
Methods: A retrospective descriptive study was performed to analyze the distribution of relative 
frequencies of clinical and laboratory variables. The study was carried out in Rio Branco 
with confirmed dengue fever cases. Secondary data were obtained by Acre Epidemiological 
Surveillance teams of cases with bleeding or platelet counts under 100.0 × 109/L. The patients’ 
clinical, laboratory and transfusion data were obtained from hospital records.
Results: A total of 90,553 dengue cases were reported of which 7,447 had serologic confirmation; 
267 cases had hemorrhagic manifestations and  193 patients were located. Nearly half of the 
patients had anemia and the mean of the lowest platelet count of these patients was 26.4 × 
109/L. Platelet concentrate was transfused in 22.3% of cases with a mean of 7.5 IU/patient, 
fresh frozen plasma in 21.2% with a mean of 5.2 IU/patient and just 2.6% of patients received 
concentrated red blood cells with a mean of 3.2 IU/patient. Bleeding led to transfusions. Signs 
of plasma leakage and cardiopulmonary dysfunction were correlated to unfavorable outcomes.
Conclusion: The pattern of clinical and laboratory criteria observed in this investigation does 
not differ from the literature. Transfusions were used as part of the treatment of dengue 
hemorrhagic fever manifestations. Some of the clinical manifestations may be related to 
unfavorable outcomes.
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Introduction
Dengue virus belongs to the genus Flavivirus (group B 
arbovirus, RNA virus) and comprises structural and non-
structural proteins.1 The classic clinical presentation is 
characterized by the abrupt onset of headache, myalgia and 
high fever, in addition to arthralgia, retro-orbital pain and 
hemorrhagic manifestations. The classical presentation 
differs from dengue hemorrhagic fever, which is characterized 
by fluid leakage into the interstitium.2 Halstead states that 
in Latin American countries including Brazil, mosquito 
eradication was achieved in large urban centers after World 
War II, however, almost 20 years after, there was a resurgence 
of Aedes populations in Brazil. This allowed the first dengue 
outbreak with viral isolation in 1981 in Boa Vista, state of 
Roraima, along with the identification of DEN-1 virus and 
later of DEN-4 virus in 2007.3 DEN-1 and DEN-2 were found 
in Rio de Janeiro in 1987 and DEN-3 in 2002. Between 2000 
and 2005, Brazilian cases represented more than 60% of 
those registered by the World Health Organization (WHO) 
and almost 80% of all cases in the Americas.4 This increase 
was identified in reports from the Brazilian Communicable 
Disease Information System.5 
A quick dengue infection confirmation test is not available, 
and a complete blood count (CBC) might show characteristics 
such as leukopenia and thrombocytopenia.6 These findings 
can be explained by peripheral platelet destruction 
mechanisms in the liver and spleen via the action of 
immunocomplexes or the complement system, in addition to 
the inhibition of medullary hematopoiesis7  and disseminated 
intravascular coagulation.8 A coagulogram might also indicate 
changes such as prolonged prothrombin and activated 
partial thromboplastin times, in addition to decreased 
serum fibrinogen concentration without increased levels of 
fibrinogen degradation products; these signs occur mainly 
with the hemorrhagic form of dengue fever.9 According to 
Lupi, “[...] Increased aspartate aminotransferase (AST) can be 
observed in 30%-90% of classic dengue cases”;8 this increase 
might correlate with thrombocytopenia, and thus, the Sri 
Lanka Medical Association considers a normal AST level to be 
a strong negative predictor of dengue hemorrhagic fever and 
its complications.10
The Ministry of Health recommends platelet transfusion 
when platelet levels are less than 20 × 109/L with significant 
bleeding or when platelet counts range from 20-50 × 109/L with 
suspected central nervous system (CNS) bleeding.2 Singhi et 
al. recommends platelet concentrate transfusions at lower 
platelet counts (10 x 109/L).1 The authors of a population-
based study conducted in India mentioned that 42.6% of 
the patients with confirmed dengue and thrombocytopenia 
(platelet count < 40 × 109/L) received platelet concentrate 
transfusions.11 In Singapore, platelet transfusion was 
performed in approximately 12% (249 patients) of 1,973 cases 
with a mean platelet count of 15 × 109/L.12 
The infusion of fresh frozen plasma (FFP) at a dose of 10 
mL/kg given every 8 or 12 hours according to changes in the 
coagulogram, is also recommended.2 However, a prospective, 
randomized, double-blind study was conducted to evaluate the 
efficacy of FFP versus isotonic saline solution infusions, and a 
significant increase in the platelet count was observed during 
the first 12 hours after infusion only in the FFP receiving group.1 
The municipality of Rio Branco, located in the western 
Amazon region, has shown a marked annual increase in the 
incidence of dengue infections, especially since 2009,5 and 
also an increase in the incidence of dengue hemorrhagic 
fever. Patients rely on emergency and urgent care services in 
two emergency healthcare units. The most serious cases and 
those that require transfusion are transferred to the Hospital 
de Urgência e Emergência de Rio Branco (HUERB).
Platelet concentrate and FFP transfusions have been used 
as a measure to prevent the increasing clinical evolution of 
dengue hemorrhagic fever, thus preventing  evolution of the 
disease towards death. Nevertheless, the criteria for making 
a decision regarding the implementation of transfusion are 
not clearly defined, and therefore such decisions are made 
relatively empirically, based on the experience of emergency 
center health professionals.
Objective
This study sought to determine the clinical and laboratory 
characteristics, transfusion aspects and mortality of patients 
with dengue hemorrhagic fever treated by emergency services 
in the city of Rio Branco, Acre.
Methods
This retrospective descriptive study employed secondary 
data on dengue cases confirmed via serology by the State 
Epidemiological Surveillance Service. Only cases with bleeding 
or platelet counts less than 100 × 109/L from January 3rd, 2007 
to June 14th, 2011 were included. Additional information was 
obtained from the medical records of the health services. 
Anemia was defined as hemoglobin levels less than 13.0 g/dL 
or hematocrit less than 40% for males, and a hemoglobin level 
less than 11.5 g/dL or hematocrit less than 36% for females at 
any point during hospitalization. Eosinophilia was defined as 
an eosinophil count above the normal range (0.04-0.4 × 109/L) 
at any point during hospitalization. This project was approved 
by the Research Ethics Committee of the Universidade Federal 
do Acre (UFAC; number 23107.011739/2011-15). A relative 
frequencies analysis of clinical and laboratory variables and 
transfusion aspects was performed, and the distribution of 
parameters was determined with 95% confidence intervals. 
Additionally, the possible effect on mortality was compared 
between groups that did or did not receive platelet concentrate 
or FFP transfusions, according to the chi-squared method with 
the level of significance being set at 5%.
Results
A total of 90,553 dengue cases were reported in Rio Branco 
during the study period.  Serology was performed in 
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16.5% (14,985 cases) cases, 7,447 serologically confirmed 
(49.7%; Figure 1). Among the confirmed cases, 7,144 (99.6%) 
were classified as classic dengue, whereas 267 cases with 
hemorrhagic manifestations were identified as hemorrhagic 
dengue according to criteria set by this study. A subsequent 
survey identified the location of 193 of the latter cases (72.3%) 
in the medical records. A predominance of female patients 
was observed (57.0% of the hemorrhagic manifestation cases). 
The mean and median patient ages were 38.2 and 35 years, 
respectively (95% confidence interval [95% CI]: 35.3-41.2 years). 
The most frequently reported signs and symptoms, listed 
in order of incidence, were fever, headache and myalgia (Table 
1). Bleeding occurred in 35.8% of the cases (95% CI: 29.0-43.0) 
and was mainly distributed as petechiae (14.0%), gingival 
bleeding (13.0%) and epistaxis (10.9%).
Plasma leakage was observed in 10.4% of the cases (95% 
CI: 6.4-15.6) and hypotension and hemodynamic instability 
occurred in 65.0% and 20.0% of these cases, respectively.
Fourteen cases (7.3%) evolved to death and 15 cases (7.8%) 
required intensive care. Among the observed complications, 
cardiorespiratory dysfunction was the most common 
affecting 5.7% of the cases, followed by ascites (4.7%) and 
pleural effusion (3.6%; Table 2). 
Signs and symptoms n % 95% CI
Fever 154 79.8 73.4-85.2
Headache 112 58.0 50.7-65.1
Myalgia 108 56.0 48.7-63.1
Abdominal pain 79 40.9 33.9-48.2
Arthralgia 68 35.2 28.5-42.4
Vomiting 56 29.0 22.7-36.0
Retro-orbital pain 31 16.1 11.2-22.0
Skin rash 27 14.0 9.4-19.7
Lethargy 21 10.9 6.9-16.2
Itching 17 8.8 5.2-13.7
Respiratory distress 12 6.2 3.3-10.6
Painful hepatomegaly 2 1.0 0.1-3.7
95% CI: 95% confidence interval.
Table 1 - Clinical characteristics in patients with dengue 
hemorrhagic fever admitted to emergency care services 
in Rio Branco, Acre from January 2007 to May 2011.
 n % 95% CI
Complications
   Cardiorespiratory dysfunction 11 5.7 2.9-10.0
   Ascites 9 4.7 2.2-8.7
   Pleural effusion 7 3.6 1.5-7.3
   Central nervous system 5 2.6 0.8-5.9
   Others 4 2.1
Evolution
   ICU transfer 15 7.8 4.4-12.5
   Death 14 7.3 4.0-11.9
95% CI: 95% confidence interval; ICU: intensive care unit.
Table 2 - Clinical complications of patients with dengue 
hemorrhagic fever admitted to the emergency care 
services in Rio Branco, Acre from January 2007 to May 
2011.
Figure 1 – Hierarchical scheme of the first analysis of dengue 
cases in the city of Rio Branco, in the period 2007-2011.
,
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Table 1 shows the frequency distributions of the clinical 
characteristics at diagnosis and the pattern of clinical 
evolution observed in this study. Of the 193 medical records, 
29 patients (15.0%; 95% CI: 10.3-20.9) reported some type of 
comorbidity. The most frequently reported comorbidity, in 
41.4% (95% CI: 23.5-61.1) of the reports, was hypertension. Regarding the CBC, anemia was observed in 45.0% of the 
cases (95% CI: 37.8-52.4), and the mean lowest hemoglobin 
level of all patients who received any type of transfusion 
during hospitalization was 9.0 g/dL. Eosinophilia was observed 
in 17.6% of the cases (95% CI: 12.5-23.9).
Several platelet counts were performed for each patient 
during hospitalization. A mean platelet count of 26.4 x 109/L 
(95% CI: 23.7-29.1 × 109/L), with a minimum value < 1 × 109/L of 
blood was observed when the lowest values for each patient 
were considered. The mean platelet count upon hospital 
discharge was 111.2 × 109/L (95% CI: 97.8-124.7 × 109/L). The 
mean lowest leukocyte count was 4.6 × 109/L (95% CI: 3.8-5.3 × 
109/L), with a minimum value of 0.7 x 109/L and a maximum 
value of 57.0 × 109/L (Table 3).
The mean AST level was 309.7 IU/L (95% CI: 140.7-478.7 IU/L), 
with minimum and maximum values of 18 and 6,390 IU/L, 
respectively. For alanine aminotransferase (ALT), the mean 
value was 167.6 IU/L (95% CI: 105.6-229.7 IU/L), with minimum 
and maximum values of 21 and 2,296 IU/L, respectively (Table 3).
Table 4 shows usage of blood component transfusions. 
In this study, 32.1% of all patients received some type 
of transfusion. Of those, 10.9% received only platelet 
concentrate, 9.8% received only FFP and 11.4% received both 
blood components.
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Of the 43 patients who received platelet concentrate, a 
mean of 7.5 IU of platelet concentrate was infused per patient 
with a median of 6 IU per patient. Of the 41 patients who 
received FFP, a mean of 5.2 IU were infused per patient with a 
median of 4 IU per patient. Only five patients received packed 
red blood cells, with an infusion mean of 3.2  IU per patient 
and a median of 3 IU per patient.
Additionally, 12.9% (8/62) of the patients who received 
FFP and/or platelet transfusions evolved to death, compared 
with 4.6% (6/131) of those who did not receive transfusions. 
This high mortality rate associated with transfusion was 
statistically significant (p-value = 0.037).
Discussion
Dengue is an infectious disease with persistent occurrence, 
especially in developing countries. Despite recent economic 
growth, success in controlling this disease has not been 
achieved, and dengue has evolved from cyclic epidemic 
outbreaks to a lack of seasonality, given the increase in new 
and relapsed cases. All of these factors have contributed to 
the rise in frequency of complications and the development 
of severe disease forms. The lack of technical support and 
scientific basis for the proper management of cases with 
hemorrhagic manifestations, especially regarding transfusion 
procedures, might contribute to the occurrence of death in 
potentially avoidable cases.
Females were predominant in this study, accounting for 
57% cases in comparison to the 48% reported in Indonesia.13 
The mean patient age in our study was 38.2 years (95% CI: 
35.3-41.2 years), higher than that reported by Brito14 in 2007 
for a 13-year period in Brazil and for a 25-year period in 
India.15 These differences in age groups can be attributed to 
the case selection criteria and the types of existing coverage 
in the hospitals where the studies were conducted.
On assessing the distributions of observed clinical 
manifestations, fever and headache were the most frequent, 
results that are in agreement with several studies in the 
literature.
The analysis of bleeding manifestations in this sample, 
the magnitude of its occurrence was higher compared to that 
reported in the literature. In this study, bleeding occurred 
in 35.8% of cases most commonly displayed as petechiae, 
gingival bleeding and epistaxis. In Thailand, the occurrence 
of hemorrhagic manifestations was reported in 50.2% of 175 
pediatric patients, and these cases included hematemesis in 
addition to petechiae and epistaxis.16  In Indonesia, bleeding 
occurred in 6% of the cases with gastrointestinal sites being 
the most common.13  Another study from India reported that 
15.1% of patients exhibited bleeding, with petechiae (9.3%) 
and epistaxis (2.7%).11 Despite the concern of hemorrhagic 
manifestations, Chaudhary et al. concluded that there was no 
correlation between hemorrhagic manifestations and serum 
platelet counts.15 These data from the literature hinder a 
better comparison of results, mainly due to differences in the 
patient selection criteria.
The occurrence of hematocrit changes in this study 
also differed from those reported in the literature. In the 
Regarding transfusions in reference to the type of blood 
component and transfusion reaction, the following results 
were observed: platelet concentrate was administered to 22.3% 
of the patients with 7.1% exhibiting transfusion reactions, and 
FFP was administered to 21.2% with 2.5% exhibiting transfusion 
reactions. Only 2.6% of the patients received packed red blood 
cells, and none reported transfusion reactions (Table  4). Of 
the four patients who received platelets or FFP and exhibited 
transfusion reactions, two had allergic reactions; the types 
of transfusion reactions were not described for the other 
patients.
Variable n %  95% CI
Anemiaa 86 45.0 37.8-52.4
Eosinophiliab 33 17.6 12.5-23.9
Mean SD Median (95% CI)
Platelets (×109/L)
At discharge 111.2 82.8 88.0 97.8-124.7
Lowest 26.4 17.4 21.8 23.7-29.1
Leucocytes (×109/L)
Lowest count 4.6 5.0 3.5 3.8-5.3
Transaminases
AST (IU/L) 309.7 788.2 174 140.7-478.7
ALT (IU/L) 167.6 287.7 99 105.6-229.7
95% CI: 95% confidence interval; AST: aspartate transaminase; ALT: 
alanine aminotransferase. 
a There was no erythrogram value for one patient. 
b There were no eosinophil values for eight patients.
Table 3 - Description of hematic characteristics of 
patients with dengue hemorrhagic fever in the city of 
Rio Branco, Acre from January 2007 to May 2011. 
Variable n %  95% CI
Transfusions by patient
   No 131
   Yes 62 32.1 25.6-39.2
Blood component transfused
   Platelet concentrate 21 10.9 6.9-16.2
   FFP 19 9.8 6.0-14.9
   Platelet concentrate and FFP 22 11.4 7.3-16.7
Transfusions by blood component
   Platelet concentrate 43 22.3 16.6-28.8
   FFP 41 21.2 15.7-27.7
   Packed red blood cells 5 2.6 0.8-5.9
95% CI: 95% confidence interval; FFP: fresh frozen plasma.
Table 4 - Blood component transfusion characteristics 
of patients with dengue hemorrhagic fever in the city of 
Rio Branco, Acre, from January 2007 to May 2011.
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present study, 45% of patients had anemia at some point 
during hospitalization. In 2006, Chaudhary et al. reported 
a mean hematocrit of 35.4%.15 Collection of the mean 
erythrocyte parameters only upon admission is insufficient 
since hematocrit variations can occur as a result of the 
hydroelectrolytic status during patient hospitalization or 
because of  bleeding that can lead to a reduced hematocrit.
In Brazil, changes in transaminases have been described in 
more than 80% of the cases,14 a rate similar to that observed 
in this study, in which 95% of the cases had AST levels ranging 
from 140.7-478.7 IU/L and ALT levels ranging from 105.6-229.7 
IU/L. These results demonstrate the importance of laboratory 
assessment upon admission and during hospitalization. 
Additionally, there is evidence of a correlation between the 
increase in these parameters and mortality. An association 
of these test results with liver dysfunction and acquired 
coagulopathy should be considered as an indication of the 
need to monitor the coagulation status and FFP transfusions.
In Thailand, 10.6% of patients with dengue hemorrhagic 
fever received some form of transfusion, and 6.9% of these 
received platelet concentrate, 5% received FFP and 3.1% received 
packed red blood cells.16 In India, a group of patients received 
platelet concentrate; among these cases, 31.8% were considered 
inappropriate transfusions and 26.9% received FFP.15 
In Singapore, 12.6% of patients received platelet 
transfusions.12 In India, 42.6% of patients received platelet 
concentrates, 5% received plasma and 2.2% received packed red 
blood cells.11 In Indonesia, platelet concentrate transfusions 
were performed in 12% of cases, with no significant 
difference in the incidence of hemorrhagic manifestations 
when compared with the group that did not receive platelet 
transfusions, even in patients with platelet counts < 25.0 × 
109/L.13 However, this study also showed that 56.5% of patients 
who received platelet concentrate transfusions had platelet 
counts higher than  100.0 × 109/L and 1.4% presented some 
type  of bleeding.
In the present study, 32.1% of patients received some 
form of transfusion; 22.3% of those patients received platelet 
concentrate, 21.2% received FFP and only 2.6% received packed 
red blood cells.
In an observational study of dengue patients in Martinique, 
several received platelet concentrate transfusions. Of the 350 
evaluated cases, 9 (2.6%) received platelet transfusions, with 
a mean of 3.66 IU per patient (range: 2.8-13.2 IU), 3 (8.6%) 
received packed red blood cells and 2 (0.6%) received FFP.17 In 
India, 3.4 IU of platelet concentrate were infused per patient,15 
a substantially smaller volume than that documented in our 
study (7.5 IU per patient).
The reported mortality in a study from Thailand was 
1.14%,16 while  mortality rates in Martinique and India were 
less than 1%17 and 2%, respectively;14 all of these rates were 
lower than the 7.3%, observed in this study. The presence 
of bleeding or clinical severity increases the indication for 
transfusions, and the indicators of plasma leakage and 
elevated transaminase levels might be related to increased 
mortality.
The apparent association of plasma and platelet concentrate 
transfusions with death requires a better evaluation because 
there is a possibility that these patients evolved with more 
severe clinical conditions that might explain the higher 
mortality in this group and why transfusion could not change 
the outcome.
Conclusion
The distribution patterns of clinical and laboratory criteria 
observed did not differ substantially from those described 
in the literature, despite the differences in sample selection 
criteria between studies. The clinical profile of the patients 
in our study can be characterized by the presence of fever, 
headache and myalgia; with petechiae, gingival bleeding and 
epistaxis as the most frequent sites of bleeding. Regarding the 
erythrocyte parameters, anemia was a frequent finding and 
the mean of the lowest platelet count for each patient upon 
admission was 26.4 × 109/L. Transaminases were elevated in 
most patients. Cardiorespiratory dysfunction was the most 
frequently observed complication.
Transfusion was used as part of the treatment regimen for 
dengue hemorrhagic fever in one-third of the cases, with a 
mixed platelet concentrate and plasma transfusion applied 
in approximately 10% of the cases. In our study, the use of 
transfusion therapy did not reduce mortality with death 
occurring in 7.3% of the cases. The results of this study suggest 
the need for more appropriate studies to assess survival in 
a cohort of patients with severe dengue and hemorrhagic 
manifestations.
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